Abstract
Recurrent somaticASXL1 mutations occur in patients with myelodysplastic syndrome, myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with adverse outcome. Despite the genetic and clinical data implicating ASXL1 mutations in myeloid malignancies, the mechanisms of transformation by ASXL1 mutations are not understood. Here, we identify that ASXL1 mutations result in loss of polycomb repressive complex 2 (PRC2)-mediated histone H3 lysine 27 (H3K27) tri-methylation. Through integration of microarray data with genome-wide histone modification ChIP-Seq data, we identify targets of ASXL1 repression, including the posterior HOXA cluster that is known to contribute to myeloid transformation. We demonstrate that ASXL1 associates with the PRC2, and that loss of ASXL1 in vivo collaborates with NRASG12D to promote myeloid leukemogenesis.
Original language | English (US) |
---|---|
Pages (from-to) | 180-193 |
Number of pages | 14 |
Journal | Cancer cell |
Volume | 22 |
Issue number | 2 |
DOIs | |
State | Published - Aug 14 2012 |
Funding
This work was supported by a grant from the Starr Cancer Consortium to R.L.L. and B.E.B., by grants from the Gabrielle's Angel Fund to R.L.L. and O.A.-W., by a grant from the Anna Fuller Fund to R.L.L., and by an NHLBI grant to B.E.B. (5U01HL100395). I.A. and B.E.B. are Howard Hughes Medical Institute Early Career Scientists. A.M. is a Burroughs Wellcome Clinical Translational Scholar and Scholar of the Leukemia and Lymphoma Society. X.Z. and S.D.N. are supported by a Leukemia and Lymphoma Society SCOR award, and F.P. is supported by an American Italian Cancer Foundation award. O.A.-W. is an American Society of Hematology Basic Research Fellow and is supported by a grant from the NIH K08 Clinical Investigator Award (1K08CA160647-01). J.P.P. is supported by an American Society of Hematology Trainee Research Award.
ASJC Scopus subject areas
- Oncology
- Cancer Research